摘要
1例胃癌患者经外周静脉穿刺中心静脉置管术(peripherally inserted central catheter,PICC)后发生导管相关颈静脉血栓,临床药师结合国内外权威指南、大型随机对照研究及患者实际情况等因素,评估患者无抗凝禁忌后建议首选低分子肝素(low molecular weight heparin ,LMWH),可选利伐沙班等方案,并结合充分的患者用药教育给予个性化抗凝治疗监护。LMWH抗凝治疗后患者颈静脉血栓有部分再通,利伐沙班维持治疗期间,未再新发血栓。临床药师对癌症相关静脉血栓患者抗凝药物实施个体化方案的用药监护,可保证患者合理用药的同时提高依从性。
One patient with gastric cancer developed catheter-related jugular vein thrombosis after peripherally inserted central catheter(PICC),combined with domestic and foreign authoritative guide,large randomized controlled research and actual situation of patients,clinical pharmacists advised low molecular weight heparin(LMWH)was the preferred choice after the evaluation of patients with no active bleeding and other anticoagulant taboos,rivaroxaban and other options could be selected.Personalized anticoagulant treatment monitoring was given in combination with adequate medication education for patients.After LMWH anticoagulation therapy,the jugular venous thrombosis of patient was relieved,and no new thrombosis occurred during the time of rivaroxaban maintenance therapy.Medication monitoring of individualized anticoagulant regimens by clinical pharmacists can ensure reasonable medication,and as well as improve the compliance of patients.
作者
白帆
都丽萍
BAI Fan;DU Li-ping(Department of Pharmacy,Peking Union Medical College Hospital,Chinese Academy of Science,Beijing 100730,China)
出处
《临床药物治疗杂志》
2019年第9期86-89,共4页
Clinical Medication Journal
基金
首都卫生发展科研专项项目(首发-2018-3-4017)
关键词
癌症
静脉血栓
抗凝治疗
依从性
低分子肝素
cancer
vein thrombosis
anticoagulant therapy
compliance
low molecular weight heparin
